PTAB: Success by the Numbers

PTAB: Success by the Numbers

Thursday, December 10th, 2015 at 10:30 am United States (GMT -07:00) Pacific

Speaker: John Callahan, partner in the Washington, DC office of Sughrue Mion

Navigation: Home > IP Matters Webinars > PTAB: Success by the Numbers

Mr. Callahan will provide a review of key aspects of successful practice before the PTAB – what do the statistics show and what does the PTAB require from a petitioner and patent owner.

This webinar is the first in Patexia's Spotlight on PTAB series, continuing with five additional speakers through March 2016.

Suggested Audience: IP practitioners working with law firms and operating companies, Companies considering using an AIA review to invalidate a patent asserted against them, licensing professionals interested in validity issues

About the Speaker

John Callahan is a partner in the firm’s Washington, DC office. He is a three-term prior member of the ‎firm’s management committee. His practice includes all aspects of Intellectual Property law, with a particular focus on ‎district court litigation and post-grant proceedings before the Patent Trial and Appeal Board of the U.S. ‎Patent and Trademark Office. In addition to his litigation and practice before the PTAB, Mr. Callahan counsels a variety of international and domestic clients regarding U.S. IP law, ‎including providing clearance, enforceability and validity opinions. He also counsels clients on licensing ‎matters and assists clients in the procurement of both U.S. and foreign patents. Mr. Callahan’s experience ‎includes the specialized U.S. practice of inter partes review, post grant review, ex parte reexamination, reissue and interferences.‎

Mr. Callahan’s practice has encompassed a wide range of technologies in the chemical, biotechnology, ‎mechanical and electrical arts, including pharmaceuticals, food chemistry, medical devices, polymers, ‎catalysts, glass products, semiconductor devices and electronic circuitry. Mr. Callahan has lectured widely ‎on U.S. IP law, particularly on the USPTO's post grant procedures implemented pursuant to the America Invents ‎Act. He has lectured in the United States, Europe, Korea, Japan, India and China on topics including ‎strategies relating to post grant proceedings at the USPTO, what constitutes ‎prior art under the America Invents Act, opinion writing, generic drug litigation, case law from the U.S. Court ‎of Appeals for the Federal Circuit, claim drafting for biotech inventions, reexamination, interferences, the ‎doctrine of equivalents and changes in U.S. patent laws and procedures.‎